Clinical trials
Aggression clinical trials
Below are recruiting aggression clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT04948749Recruiting
Stenting plus medication to prevent stroke from narrowed brain arteries
This trial tests whether placing a stent in a severely narrowed brain artery, along with aggressive medication, can prevent another stroke better than medication alone. It is for people who had a mild stroke within the last 30 days due to a 70-99% blockage in a major brain artery.
Beijing, Beijing MunicipalityAges 18–85 - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT05974696Recruiting
Registry for aggressive pituitary tumors (Aggressive PitNETs)
This study is a research registry that collects information from people with aggressive pituitary tumors. It may help researchers better understand these tumors by building a large, shared dataset over time.
LyonAges 18 years+ - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+ - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT07782398Recruiting
Smartphone stress prompts and hair steroid levels in college students
This study tests whether brief prompts to help you cope with stress, sent to your smartphone, can improve your wellbeing. It will also look at stress hormones in hair as a way to measure long-term stress levels.
Gainesville, FloridaAges 18–89 - NCT07755176Enrolling by invitation
Desmoid tumor ablation recovery survey
This study follows patients with desmoid tumors who are having a procedure called ablation, which uses heat or cold to destroy the tumor. The study asks patients about their symptoms and quality of life after the procedure to see how well it works.
Rochester, MinnesotaAges 18 years+ - NCT07727083Recruiting
Study of EBV-positive T/NK-cell lymphoma and related diseases
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06607731Recruiting
Alcohol gel treatment for aggressive angiomas
This trial studies a treatment using a special gelled alcohol to shrink aggressive angiomas (abnormal blood vessel growths). It aims to see if the procedure is safe, feasible, and works well.
Saint-Priest-en-JarezAges 18 years+ - NCT07704918Recruiting
Study: Lowering cholesterol during melanoma immunotherapy
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
Aurora, ColoradoAges 55 years+ - NCT07398170Recruiting
Searching for tumor cells in fluid for recurrent meningioma
This study looks for tumor cells in your blood or spinal fluid to see if they can help track aggressive meningiomas that have come back. It may help doctors understand your cancer better and guide future treatments.
Montpellier, FranceAges 18 years+ - NCT05793034Recruiting
Study factors that predict survival after aggressive meningioma surgery
This study looks at people who had surgery for more aggressive meningiomas (grade 2 or 3) and tries to learn what factors relate to survival. The results may help doctors better predict outcomes for future patients.
RomeAges 18 years+ - NCT06877065Recruiting
MRI-Guided Fertility Preservation for Cervical Cancer
This study uses MRI scans to see if women with early-stage cervical cancer can safely keep their fertility. It follows patients before and after treatment to find which factors might lead to more aggressive disease.
RomeAges 18 years+ - NCT06118567RecruitingPhase 2
Does nitrous oxide help with aggression?
This study tests if a single dose of nitrous oxide (laughing gas) can reduce aggression in people with intermittent explosive disorder (IED). It compares their reactions to healthy volunteers without aggression issues.
Columbus, OhioAges 21–55 - NCT05895513RecruitingPhase 2
Pimavanserin trial for aggression and social thinking
This Phase 2 trial tests pimavanserin, a medication that may affect brain signals, to see if it can reduce aggression and improve social thinking in people with intermittent explosive disorder (IED) or a history of aggressive behavior. If you qualify, you’ll be screened with medical tests and questionnaires and must meet medication and safety rules to participate.
Columbus, OhioAges 21–55 - NCT05765864Recruiting
Study of self-harm in at-risk teens
This study looks at self-harm and thoughts/behaviors related to safety in teenagers who are considered at higher risk. It may help researchers better understand what supports are needed for teens who self-harm without wanting to die.
LjubljanaAges 13–18 - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07202559Recruiting
Preventing Pancreatitis After Shock Wave Therapy for Pancreatic Stones
This study tests whether a combination of an NSAID (indomethacin) given rectally plus extra fluids through an IV can prevent pancreatitis after shock wave therapy for pancreatic stones. It may help reduce inflammation and protect your pancreas during treatment.
BaotouAges 18–85 - NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+ - NCT05257629RecruitingPhase 3
Aggressive smoking quit program after heart problems
This trial tests whether a strong quit plan using varenicline (a quit pill) plus nicotine e-cigarettes, along with counseling, helps people stop smoking after a recent heart-related event. It’s aimed at people who want to quit and can safely stay involved for about a year.
New Westminster, British ColumbiaAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07176689RecruitingPhase 4
Nirogacestat for desmoid tumors in premenopausal women
This trial tests a drug called nirogacestat to see if it can help premenopausal women with desmoid tumors (a type of non-cancerous growth) that are causing symptoms or getting worse. It aims to offer a new treatment option for those who need systemic therapy.
BrusselsAges 18–40
Hear when a new Aggression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for aggression?
- Yes. Clin2 currently lists 88 recruiting aggression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a aggression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.